Navigating the AI Landscape in Healthcare: Ethics and Access

By Sumona Bose

December 11, 2023

The AI Challenge in Healthcare

The integration of Artificial Intelligence (AI) into the healthcare sector is a complex endeavour. Life sciences consulting firms are grappling with significant challenges, particularly when it comes to embedding AI-enabled diagnostics into healthcare systems. These challenges are rooted in sociocultural, technological, and institutional subsystems. The medical community’s prevailing ethos, concerns about black-box decision-making, and fear of reputational harm are some of the factors contributing to resistance against AI.

The Response: Stealth Science, Agility, and Digital Ambidexterity

AI providers are responding to these challenges with three key practices: stealth science, agility, and digital ambidexterity. Stealth science involves maintaining opacity around development to safeguard trade secrets and evade regulatory scrutiny. Agility refers to the capacity to adapt to different technical settings and learn from various healthcare environments. Lastly, digital ambidexterity is the pursuit of efficiency and innovation in developing AI technologies.

However, these practices may lead to complexities in technology spread, regulatory challenges, and shifts in healthcare dynamics. It’s clear that the journey towards integrating AI into healthcare is filled with paradoxes, with AI providers having to tread a fine line between acceleration and inertia.

The Ethical Considerations

From policy makers, ethics in access to AI is an important factor to consider. AI providers need to ensure that their practices allow for more latitude in navigating healthcare systems, but this must be balanced against the need for transparency and accountability.

To ensure value-based healthcare, we must address these ethical dilemmas head-on and work towards finding workable solutions. AI consulting firms must work in tandem with healthcare providers and policy-makers to create human-centred solutions that respect the rights and needs of all stakeholders.

Reference url

Recent Posts

Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Patient-reported outcomes trends show a clear surge in clinical trials from 2008 to 2023, where usage has doubled in interventional studies, while tools like EQ-5D lead as the top generic instrument, with PROMIS seeing e...
Addressing AI Polyp Detection Gaps: A Roadmap for Evidence Generation and NHS Integration
Addressing Evidence Gaps in AI Polyp Detection AI Polyp Detection Gaps persist in colorectal cancer screening, as highlighted by the National Institute for He...